Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 4/20 | 0.60 |
| ▸ | MC5R | P33032 | 3/20 | 0.60 |
| ▸ | MC3R | P41968 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874992 | 1.00 | MC1R (0.60) | MC1RMC5RMC3RKDM4EMAPT | |
| SCHEMBL26292984 | 0.86 | MC1R (0.59) | MC1RMC5RMC3RKDM4EMAPT | |
| SCHEMBL29489675 | 0.85 | MC5R (0.66) | MC1RMC5RMC3RKDM4EMAPT | |
| SCHEMBL660463 | 0.85 | MC5R (0.66) | MC1RMC5RMC3RKDM4EMAPT | |
| SCHEMBL468296 | 0.82 | LMNA (0.65) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29411993 | 0.82 | LMNA (0.65) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4079184 | 0.81 | MGAM (0.53) | MC1RMC5RMC3RMAPTMEN1 | |
| SCHEMBL11568830 | 0.80 | MC1R (0.59) | MC1RMC5RMC3RKDM4EMAPT | |
| SCHEMBL31370294 | 0.80 | GLS (0.46) | MC1RMC5RMC3RKDM4EMAPT | |
| Indolylpropionic Acid SCHEMBL29374161 | 0.79 | MAPT (0.68) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080233137-A1 | Compounds that Block the C5a Receptor and Their Use in Therapy | ALLIGATOR BIOSCIENCE AB (SE) | 2008-09-25 | — | — | US | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| CN-1997664-A | Compounds that block the C5A receptor and their use in therapy | ALLIGATOR BIOSCIENCE AB PUBL (SE) | 2007-07-11 | — | — | CN | claimed |
| EP-1737886-A2 | COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY | Alligator Bioscience AB (publ) (SE) | 2007-01-03 | — | — | EP | claimed |
| WO-2005100385-A2 | COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY | ALLIGATOR BIOSCIENCE AB (PUBL) (SE) | 2005-10-27 | — | — | WO | claimed |
| EP-1586583-A2 | Compounds that block C5a complement receptor and their use in therapy | Alligator Bioscience AB (publ) (SE) | 2005-10-19 | — | — | EP | claimed |
| WO-2003006048-A1 | COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS | JARI PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | claimed |
| WO-2024118635-A2 | THERMOSTABLE BINDING SCAFFOLDS | NECTAGEN, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182532-A1 | MICROPEPTIDES AND USES THEREOF | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-06-06 | — | — | US | disclosed |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11986522-B2 | Immunotherapeutic composition and uses thereof | ARA VAX PTY LTD (AU) | 2024-05-21 | — | — | US | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11980658-B2 | Immunotherapeutic molecules and uses thereof | ARAVAX PTY LTD (AU) | 2024-05-14 | — | — | US | disclosed |
| WO-1997023629-A1 | A NOVEL RECEPTOR-TYPE TYROSINE KINASE AND USE THEREOF | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023501-A1 | THERAPEUTIC COMPOSITIONS | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997021727-A1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | THE UNIVERSITY OF MELBOURNE (AU) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997016202-A1 | CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997015663-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997012037-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997004091-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | FCGR3B, FCGRT, FCGR2A | MC1R 3614/4885MC5R 3026/4885MC3R 3386/4885 |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | MC1R 4399/4885MC5R 4137/4885MC3R 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.